Skip to main content
Erschienen in: Breast Cancer Research 5/2009

01.10.2009 | Review

Update on the use of aromatase inhibitors in early-stage breast cancer

verfasst von: Georgios Kesisis, Andreas Makris, David Miles

Erschienen in: Breast Cancer Research | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treatment options. Recent publications provide conflicting advice on the role of aromatase inhibitors in the treatment of postmenopausal patients with early-stage hormone receptor-positive breast cancer. This review provides updates on the clinical trials of aromatase inhibitors in early breast cancer and tries to provide practical clinical guidance on their optimal use.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef
2.
Zurück zum Zitat Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000, 18: 3748-3757.PubMed Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000, 18: 3748-3757.PubMed
3.
Zurück zum Zitat Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomized trial. J Clin Oncol. 2000, 18: 3758-3767.PubMed Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomized trial. J Clin Oncol. 2000, 18: 3758-3767.PubMed
4.
Zurück zum Zitat Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee; Investigators Committee Members: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer. 2001, 92: 2247-2258. 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y.CrossRefPubMed Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee; Investigators Committee Members: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer. 2001, 92: 2247-2258. 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y.CrossRefPubMed
5.
Zurück zum Zitat Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III Study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003, 21: 2101-2109. 10.1200/JCO.2003.04.194.CrossRefPubMed Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III Study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003, 21: 2101-2109. 10.1200/JCO.2003.04.194.CrossRefPubMed
6.
Zurück zum Zitat Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res. 1997, 3: 1101-1108.PubMed Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res. 1997, 3: 1101-1108.PubMed
7.
Zurück zum Zitat di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC: Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1992, 43: 137-143. 10.1016/0960-0760(92)90198-R.CrossRefPubMed di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC: Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1992, 43: 137-143. 10.1016/0960-0760(92)90198-R.CrossRefPubMed
8.
Zurück zum Zitat Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005, 23: 619-629. 10.1200/JCO.2005.09.121.CrossRefPubMed Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005, 23: 619-629. 10.1200/JCO.2005.09.121.CrossRefPubMed
10.
Zurück zum Zitat Chlebowski RT: Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. Breast Cancer Res Treat. 2008, 112: 25-34. 10.1007/s10549-008-0237-5.CrossRefPubMed Chlebowski RT: Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. Breast Cancer Res Treat. 2008, 112: 25-34. 10.1007/s10549-008-0237-5.CrossRefPubMed
11.
Zurück zum Zitat Seruga B, Tannock IF: Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol. 2009, 27: 840-842. 10.1200/JCO.2008.19.5594.CrossRefPubMed Seruga B, Tannock IF: Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol. 2009, 27: 840-842. 10.1200/JCO.2008.19.5594.CrossRefPubMed
12.
Zurück zum Zitat Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139. 10.1016/S0140-6736(02)09088-8.CrossRefPubMed Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002, 359: 2131-2139. 10.1016/S0140-6736(02)09088-8.CrossRefPubMed
13.
Zurück zum Zitat Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008, 9: 45-53. 10.1016/S1470-2045(07)70385-6.CrossRef Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008, 9: 45-53. 10.1016/S1470-2045(07)70385-6.CrossRef
14.
Zurück zum Zitat Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005, 353: 2747-2757. 10.1056/NEJMoa052258.CrossRef Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005, 353: 2747-2757. 10.1056/NEJMoa052258.CrossRef
15.
Zurück zum Zitat Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007, 25: 486-492. 10.1200/JCO.2006.08.8617.CrossRefPubMed Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007, 25: 486-492. 10.1200/JCO.2006.08.8617.CrossRefPubMed
16.
Zurück zum Zitat Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M, Thuerlimann B, Forbes JF, Gelber RD, Wardley A, Smith I, Price KN, Coates A, Goldhirsch A, BIG I-98 Collaborative and the International Breast Cancer Study Group: BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract 13]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14. 2008, [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_553&terms=]December ; San Antonio, TX Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M, Thuerlimann B, Forbes JF, Gelber RD, Wardley A, Smith I, Price KN, Coates A, Goldhirsch A, BIG I-98 Collaborative and the International Breast Cancer Study Group: BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract 13]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14. 2008, [http://​www.​abstracts2view.​com/​sabcs/​view.​php?​nu=​SABCS08L_​553&​terms=​]December ; San Antonio, TX
18.
Zurück zum Zitat Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Velde van de C, Intergroup Exemestane Study: A randomized trial of examestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004, 350: 1081-1092. 10.1056/NEJMoa040331.CrossRefPubMed Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Velde van de C, Intergroup Exemestane Study: A randomized trial of examestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004, 350: 1081-1092. 10.1056/NEJMoa040331.CrossRefPubMed
19.
Zurück zum Zitat Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Velde Van de CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007, 369: 559-570. 10.1016/S0140-6736(07)60200-1.CrossRefPubMed Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Velde Van de CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007, 369: 559-570. 10.1016/S0140-6736(07)60200-1.CrossRefPubMed
20.
Zurück zum Zitat Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G: Improved overall survival in post-menopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007, 25: 2664-2670. 10.1200/JCO.2006.08.8054.CrossRefPubMed Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G: Improved overall survival in post-menopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007, 25: 2664-2670. 10.1200/JCO.2006.08.8054.CrossRefPubMed
21.
Zurück zum Zitat Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006, 7: 991-996. 10.1016/S1470-2045(06)70948-2.CrossRefPubMed Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006, 7: 991-996. 10.1016/S1470-2045(06)70948-2.CrossRefPubMed
22.
Zurück zum Zitat Jakesz R, Gnant M, Griel R, Tausch C, Samonigg H, Kwasny W, Kubista E, Stierer M, Luschin G, Rüecklinger E, Mittlböck M: Tamoxifen and anastrozole as a sequencing strategy in post-menopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14. 2008, [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_759&terms=]December ; San Antonio, TX Jakesz R, Gnant M, Griel R, Tausch C, Samonigg H, Kwasny W, Kubista E, Stierer M, Luschin G, Rüecklinger E, Mittlböck M: Tamoxifen and anastrozole as a sequencing strategy in post-menopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14. 2008, [http://​www.​abstracts2view.​com/​sabcs/​view.​php?​nu=​SABCS08L_​759&​terms=​]December ; San Antonio, TX
23.
Zurück zum Zitat Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, Velde van de CJH: Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract 15]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14. 2008, [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_55&terms=]December ; San Antonio, TX Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, Velde van de CJH: Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract 15]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14. 2008, [http://​www.​abstracts2view.​com/​sabcs/​view.​php?​nu=​SABCS08L_​55&​terms=​]December ; San Antonio, TX
24.
Zurück zum Zitat Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003, 349: 1793-1802. 10.1056/NEJMoa032312.CrossRefPubMed Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003, 349: 1793-1802. 10.1056/NEJMoa032312.CrossRefPubMed
25.
Zurück zum Zitat Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst. 2005, 97: 1262-1271.CrossRefPubMed Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst. 2005, 97: 1262-1271.CrossRefPubMed
26.
Zurück zum Zitat Goss PE, Ingle JN, Palmer MJ, Shepherd LE: Updated analysis of NCIC MA17 (letrozole versus placebo to letrozole versus placebo) post unblinding [abstract 16]. Breast Cancer Res Treat. 2005, 94: S1-10.1007/s10549-005-1234-6.CrossRef Goss PE, Ingle JN, Palmer MJ, Shepherd LE: Updated analysis of NCIC MA17 (letrozole versus placebo to letrozole versus placebo) post unblinding [abstract 16]. Breast Cancer Res Treat. 2005, 94: S1-10.1007/s10549-005-1234-6.CrossRef
27.
Zurück zum Zitat Pemberton KD, Melissari E, Kakkar VV: The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993, 4: 935-942.CrossRefPubMed Pemberton KD, Melissari E, Kakkar VV: The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993, 4: 935-942.CrossRefPubMed
28.
Zurück zum Zitat Love RR, Surawicz TS, Williams EC: Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. 1992, 152: 317-320. 10.1001/archinte.152.2.317.CrossRefPubMed Love RR, Surawicz TS, Williams EC: Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. 1992, 152: 317-320. 10.1001/archinte.152.2.317.CrossRefPubMed
29.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.CrossRefPubMed
30.
Zurück zum Zitat Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006, 7: 633-643. 10.1016/S1470-2045(06)70767-7.CrossRefPubMed Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006, 7: 633-643. 10.1016/S1470-2045(06)70767-7.CrossRefPubMed
31.
Zurück zum Zitat Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005, 366: 455-462. 10.1016/S0140-6736(05)67059-6.CrossRefPubMed Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005, 366: 455-462. 10.1016/S0140-6736(05)67059-6.CrossRefPubMed
32.
Zurück zum Zitat Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialists' Group: Quality of life of postmenopausal women in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006, 100: 273-284. 10.1007/s10549-006-9260-6.CrossRefPubMed Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialists' Group: Quality of life of postmenopausal women in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006, 100: 273-284. 10.1007/s10549-006-9260-6.CrossRefPubMed
33.
Zurück zum Zitat Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E: Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in post-menopausal women with primary breast cancer. J Clin Oncol. 2006, 24: 910-917. 10.1200/JCO.2005.03.3654.CrossRefPubMed Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E: Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in post-menopausal women with primary breast cancer. J Clin Oncol. 2006, 24: 910-917. 10.1200/JCO.2005.03.3654.CrossRefPubMed
34.
Zurück zum Zitat Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH: Menopausal symptoms in young breast cancer survivors. Ann Oncol. 2006, 17: 1777-1782. 10.1093/annonc/mdl299.CrossRefPubMed Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH: Menopausal symptoms in young breast cancer survivors. Ann Oncol. 2006, 17: 1777-1782. 10.1093/annonc/mdl299.CrossRefPubMed
35.
Zurück zum Zitat Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, WHEL Study Group: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008, 108: 421-426. 10.1007/s10549-007-9612-x.CrossRefPubMed Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, WHEL Study Group: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008, 108: 421-426. 10.1007/s10549-007-9612-x.CrossRefPubMed
36.
Zurück zum Zitat Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992, 326: 852-856.CrossRefPubMed Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992, 326: 852-856.CrossRefPubMed
37.
Zurück zum Zitat Coleman RE, on behalf of the ATAC Trialists' Group: Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006, 24 (June 20 Suppl): 511- Coleman RE, on behalf of the ATAC Trialists' Group: Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006, 24 (June 20 Suppl): 511-
38.
Zurück zum Zitat Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005, 23: 5126-5137. 10.1200/JCO.2005.07.097.CrossRefPubMed Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G: Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005, 23: 5126-5137. 10.1200/JCO.2005.07.097.CrossRefPubMed
39.
Zurück zum Zitat McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R: Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007, 43: 2523-2531. 10.1016/j.ejca.2007.08.029.CrossRefPubMed McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R: Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007, 43: 2523-2531. 10.1016/j.ejca.2007.08.029.CrossRefPubMed
40.
Zurück zum Zitat Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62. 10.1016/S0140-6736(05)74803-0.CrossRefPubMed Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62. 10.1016/S0140-6736(05)74803-0.CrossRefPubMed
41.
Zurück zum Zitat Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003, 98: 1802-1810. 10.1002/cncr.11745.CrossRefPubMed Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003, 98: 1802-1810. 10.1002/cncr.11745.CrossRefPubMed
42.
Zurück zum Zitat Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in post-menopausal women with early breast cancer. J Clin Oncol. 2007, 25: 829-836. 10.1200/JCO.2005.05.3744.CrossRefPubMed Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in post-menopausal women with early breast cancer. J Clin Oncol. 2007, 25: 829-836. 10.1200/JCO.2005.05.3744.CrossRefPubMed
43.
Zurück zum Zitat Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group: Zoledronic acid prevents cancer treatment-induced bone loss in pre-menopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007, 25: 820-828. 10.1200/JCO.2005.02.7102.CrossRefPubMed Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group: Zoledronic acid prevents cancer treatment-induced bone loss in pre-menopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007, 25: 820-828. 10.1200/JCO.2005.02.7102.CrossRefPubMed
44.
Zurück zum Zitat Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008, 112: 1001-1010. 10.1002/cncr.23259.CrossRefPubMed Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008, 112: 1001-1010. 10.1002/cncr.23259.CrossRefPubMed
45.
Zurück zum Zitat Burstein HJ, Winer EP: Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007, 25: 3797-3799. 10.1200/JCO.2007.11.9529.CrossRefPubMed Burstein HJ, Winer EP: Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007, 25: 3797-3799. 10.1200/JCO.2007.11.9529.CrossRefPubMed
46.
Zurück zum Zitat Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007, 25: 3877-3883. 10.1200/JCO.2007.10.7573.CrossRefPubMed Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007, 25: 3877-3883. 10.1200/JCO.2007.10.7573.CrossRefPubMed
47.
Zurück zum Zitat Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008, 26: 3147-3152. 10.1200/JCO.2007.15.4005.CrossRefPubMed Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008, 26: 3147-3152. 10.1200/JCO.2007.15.4005.CrossRefPubMed
48.
Zurück zum Zitat Herrington DM, Klein KP: Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001, 11: 95-102. 10.1016/S1049-3867(01)00075-5.CrossRefPubMed Herrington DM, Klein KP: Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001, 11: 95-102. 10.1016/S1049-3867(01)00075-5.CrossRefPubMed
49.
Zurück zum Zitat Bradbury BD, Lash TL, Kaye JA, Jick SS: Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer. 2005, 103: 1114-1121. 10.1002/cncr.20900.CrossRefPubMed Bradbury BD, Lash TL, Kaye JA, Jick SS: Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer. 2005, 103: 1114-1121. 10.1002/cncr.20900.CrossRefPubMed
50.
Zurück zum Zitat McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ. 1995, 311: 977-980.CrossRefPubMedPubMedCentral McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ. 1995, 311: 977-980.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Nabholtz J-M, Gligorov J: Comparison of cardiovascular safety profiles of aromatase inhibitors. Eur J Cancer Suppl. 2005, 3: 96- Nabholtz J-M, Gligorov J: Comparison of cardiovascular safety profiles of aromatase inhibitors. Eur J Cancer Suppl. 2005, 3: 96-
52.
Zurück zum Zitat Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R: Switching from adjuvant tamoxifen to anastrozole in post-menopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG Trial 8 and the ITA trial [abstract 18]. Breast Cancer Res Treat. 2005, 94: S1-10.1007/s10549-005-1234-6.CrossRef Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R: Switching from adjuvant tamoxifen to anastrozole in post-menopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG Trial 8 and the ITA trial [abstract 18]. Breast Cancer Res Treat. 2005, 94: S1-10.1007/s10549-005-1234-6.CrossRef
53.
Zurück zum Zitat Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A: Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004, 22: 4261-4271. 10.1200/JCO.2004.08.029.CrossRefPubMed Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A: Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004, 22: 4261-4271. 10.1200/JCO.2004.08.029.CrossRefPubMed
54.
Zurück zum Zitat Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB: Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005, 23: 6931-6940. 10.1200/JCO.2005.11.181.CrossRefPubMed Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB: Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005, 23: 6931-6940. 10.1200/JCO.2005.11.181.CrossRefPubMed
55.
Zurück zum Zitat Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early stage breast cancer. J Natl Cancer Inst. 1996, 88: 1543-1549. 10.1093/jnci/88.21.1543.CrossRef Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early stage breast cancer. J Natl Cancer Inst. 1996, 88: 1543-1549. 10.1093/jnci/88.21.1543.CrossRef
56.
Zurück zum Zitat Garber K: Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst. 2005, 97: 412-413.CrossRefPubMed Garber K: Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst. 2005, 97: 412-413.CrossRefPubMed
57.
Zurück zum Zitat Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005, 97: 30-39.CrossRefPubMed Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005, 97: 30-39.CrossRefPubMed
58.
Zurück zum Zitat Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003, 95: 1758-1764.CrossRefPubMed Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003, 95: 1758-1764.CrossRefPubMed
59.
Zurück zum Zitat Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2d6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005, 5: 6-13. 10.1038/sj.tpj.6500285.CrossRefPubMed Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2d6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005, 5: 6-13. 10.1038/sj.tpj.6500285.CrossRefPubMed
60.
Zurück zum Zitat Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN: Pharmacogenetics of tamoxifen biotrans-formation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23: 9312-9318. 10.1200/JCO.2005.03.3266.CrossRefPubMed Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN: Pharmacogenetics of tamoxifen biotrans-formation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23: 9312-9318. 10.1200/JCO.2005.03.3266.CrossRefPubMed
61.
Zurück zum Zitat Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009, 9: 576-586. 10.1038/nrc2683.CrossRefPubMed Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009, 9: 576-586. 10.1038/nrc2683.CrossRefPubMed
63.
Zurück zum Zitat Dezentje V, Van Blijderveen NJ, Gelderblom H: Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol. 2009, 27: 18s-10.1200/JCO.2009.22.4626.CrossRef Dezentje V, Van Blijderveen NJ, Gelderblom H: Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol. 2009, 27: 18s-10.1200/JCO.2009.22.4626.CrossRef
64.
Zurück zum Zitat Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008, 100: 642-648. 10.1093/jnci/djn100.CrossRefPubMedPubMedCentral Punglia RS, Burstein HJ, Winer EP, Weeks JC: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008, 100: 642-648. 10.1093/jnci/djn100.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005, 23: 5108-5116. 10.1200/JCO.2005.04.005.CrossRefPubMed Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005, 23: 5108-5116. 10.1200/JCO.2005.04.005.CrossRefPubMed
66.
Zurück zum Zitat Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A: Relationship between quantitative estrogen receptor and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol. 2008, 26: 1059-1065. 10.1200/JCO.2007.12.9437.CrossRefPubMed Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A: Relationship between quantitative estrogen receptor and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol. 2008, 26: 1059-1065. 10.1200/JCO.2007.12.9437.CrossRefPubMed
67.
Zurück zum Zitat Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005, 23: 7512-7517. 10.1200/JCO.2005.01.4829.CrossRefPubMed Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005, 23: 7512-7517. 10.1200/JCO.2005.01.4829.CrossRefPubMed
68.
Zurück zum Zitat Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992, 24: 85-95. 10.1007/BF01961241.CrossRefPubMed Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992, 24: 85-95. 10.1007/BF01961241.CrossRefPubMed
69.
Zurück zum Zitat Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999, 79: 1220-1226. 10.1038/sj.bjc.6690196.CrossRefPubMedPubMedCentral Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999, 79: 1220-1226. 10.1038/sj.bjc.6690196.CrossRefPubMedPubMedCentral
70.
Zurück zum Zitat Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003, 21: 1967-1972. 10.1200/JCO.2003.09.098.CrossRefPubMed Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003, 21: 1967-1972. 10.1200/JCO.2003.09.098.CrossRefPubMed
71.
Zurück zum Zitat Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006, 24: 3019-3025. 10.1200/JCO.2005.04.3034.CrossRefPubMed Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM: Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006, 24: 3019-3025. 10.1200/JCO.2005.04.3034.CrossRefPubMed
72.
Zurück zum Zitat Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups: BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008, 9: 23-28. 10.1016/S1470-2045(07)70386-8.CrossRefPubMed Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, BIG 1-98 Collaborative and International Breast Cancer Study Groups: BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008, 9: 23-28. 10.1016/S1470-2045(07)70386-8.CrossRefPubMed
73.
Zurück zum Zitat Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A, Breast International Group Trial 1-98: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008, 26: 5569-5575. 10.1200/JCO.2008.17.0829.CrossRefPubMedPubMedCentral Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A, Breast International Group Trial 1-98: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008, 26: 5569-5575. 10.1200/JCO.2008.17.0829.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006, 17: 818-826. 10.1093/annonc/mdl016.CrossRefPubMed Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol. 2006, 17: 818-826. 10.1093/annonc/mdl016.CrossRefPubMed
75.
Zurück zum Zitat Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.PubMed Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19: 3808-3816.PubMed
76.
Zurück zum Zitat Fisher B, Dignam J, Bryant J, Wolmark N: Five versus more than five years of tamoxifen for node-negative breast cancer: updated findings. J Natl Cancer Inst. 2001, 93: 684-690. 10.1093/jnci/93.9.684.CrossRefPubMed Fisher B, Dignam J, Bryant J, Wolmark N: Five versus more than five years of tamoxifen for node-negative breast cancer: updated findings. J Natl Cancer Inst. 2001, 93: 684-690. 10.1093/jnci/93.9.684.CrossRefPubMed
77.
Zurück zum Zitat Stewart JH, Prescott RJ, Forrest AP: Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001, 93: 456-462. 10.1093/jnci/93.6.456.CrossRefPubMed Stewart JH, Prescott RJ, Forrest AP: Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001, 93: 456-462. 10.1093/jnci/93.6.456.CrossRefPubMed
78.
Zurück zum Zitat Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst. 1996, 88: 1828-1833. 10.1093/jnci/88.24.1828.CrossRefPubMed Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst. 1996, 88: 1828-1833. 10.1093/jnci/88.24.1828.CrossRefPubMed
80.
Zurück zum Zitat Gray G, Rea DW, Handley K, Marshall A, Pritchard MG, Perry P, Earl HM, Poole CJ, Salman A, Lee M, aTTom Collaborators: aTTom (adjuvant Tamoxifen--To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. J Clin Oncol. 2008, 26: [http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/513] Gray G, Rea DW, Handley K, Marshall A, Pritchard MG, Perry P, Earl HM, Poole CJ, Salman A, Lee M, aTTom Collaborators: aTTom (adjuvant Tamoxifen--To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. J Clin Oncol. 2008, 26: [http://​meeting.​ascopubs.​org/​cgi/​content/​abstract/​26/​15_​suppl/​513]
81.
Zurück zum Zitat Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE: Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008, 34 (Suppl 1): S3-18. 10.1016/j.ctrv.2008.03.007.CrossRefPubMed Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE: Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008, 34 (Suppl 1): S3-18. 10.1016/j.ctrv.2008.03.007.CrossRefPubMed
Metadaten
Titel
Update on the use of aromatase inhibitors in early-stage breast cancer
verfasst von
Georgios Kesisis
Andreas Makris
David Miles
Publikationsdatum
01.10.2009
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2009
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2410

Weitere Artikel der Ausgabe 5/2009

Breast Cancer Research 5/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.